At the news
? BULLISHIMPACT 5/10 INSIDER-BUY filed Aug 12, 2026 at 16:04 ET
Pfizer Chairman & CEO Albert Bourla made an open-market purchase of $1.0M worth of shares at $26.34 on August 12, 2026, his first open-market buy in the reported window. This purchase follows a strong Q2 earnings beat (12.9% on adjusted EPS) and a raised revenue guidance midpoint by $500M, signaling insider conviction that the stock is undervalued despite GAAP net loss from $4.3B in intangible asset impairments. At $152.7B market cap, the $1.0M buy represents ~0.001% of market cap, proportionally tiny, but as a standalone CEO conviction buy backed by solid operational results, it carries meaningful signal per insider-trading literature.
- Chairman & CEO Albert Bourla purchased 38,000 shares at $26.34 for total of $1,000,920 on August 12, 2026
- Purchase is an open-market buy (SEC code P), not a grant or exercise, CEO is deploying personal capital
- Purchase comes 8 days after Pfizer reported Q2 2026 adjusted EPS beat of 12.9% ($0.77 vs $0.68 consensus) and raised FY2026 revenue guidance midpoint by $500M to $60.5-$62.5B
- Bourla also received a 22-share grant on August 14 ($589), de minimis, but consistent with normal administrative pattern
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access